Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 8kWORD 19k
21 November 2018
E-004938/2018(ASW)
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-004938/2018

The Commission closely follows the work of the ‘Heads of Medicines Agencies/European Medicines Agency’ task force on availability of authorised medicines(1) that deals with access and possible shortages of medicines in the Member States. The Commission also contributes in other ways to addressing issues of access and availability, for example through the expert group on Safe and Timely Access to Medicines for Patients.

The Commission proposal on Health Technology Assessment(2) has the aim and the potential to contribute to a better availability of innovative health technologies, including medicines. It foresees the development of joint clinical assessments at EU level that identify which treatments bring real added value for patients.

In relation to patient waiting times, the organisation and delivery of health service and medical care are the responsibility of the Member States, as well as the management of medical treatment(3). However, the Commission follows and analyses the effectiveness, accessibility and resilience of health systems as part of the European Semester(4).

Concerning cancer prevention, the Commission has adopted a number of tobacco control measures to reduce the risk of respiratory diseases(5). The Commission helps Member States to promote smoke-free policies and healthy life styles, and provides EU best practices and guidelines in the areas of cancer screening, quality assurance in cancer management, integrated cancer control, after-care at community level, and survivorship and rehabilitation(6).

Finally, Horizon 2020(7) has supported research on lung cancer prevention, diagnosis, treatment as well as quality-of-life of lung cancer patients(8) and will provide further funding opportunities in its last call for proposals(9).

(1)http://www.hma.eu/522.html
(2)https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51_en.pdf
(3)https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:12008E168&from=EN
(4)https://ec.europa.eu/info/business-economy-euro/economic-and-fiscal-policy-coordination/eu-economic-governance-monitoring-prevention-correction/european-semester_en
(5)https://ec.europa.eu/health/tobacco/overview_en
(6)https://ec.europa.eu/health/non_communicable_diseases/cancer_en
(7)The EU Framework Programme for Research and Innovation (2014-2020)
(8)http://cordis.europa.eu/projects/home_en.html
(9)Information will be made available on the Research and Innovation Participant Portal at: http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html

Last updated: 22 November 2018Legal notice